Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Announces Sale of Five MassArray Systems

NEW YORK, July 10 – Sequenom of San Diego said Tuesday it had sold five MassArray systems, bringing the number sold in the second quarter to nine.

The purchasers include BioServe Biotechnologies, Centagenetix, Indiana University School of Medicine, LGC, and an undisclosed party. 

"We continue to experience an increasing demand for our MassArray product line," Toni Schuh, CEO of Sequenom, said in a statement.

"The success of our systems business also affords us the opportunity to expand our efforts to include the systematic identification of disease genes with the most significant impact on human health,” he said.

Sequenom did not say how much the systems sold for, but in the past the company has said that the price of the MassArray is between $400,000 and $1.1 million depending on consumables. 

Schuh said that Sequenom hopes to forge licensing deals and partnerships for a sizable number of the 50 candidate disease genes the company has identified, while keeping some of the more interesting targets for internal development.

In May, Sequenom announced that it would acquire Britain’s Gemini Genomics as part of its hstrategy to become a drug developer.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.